News
Business
Medical
Research
Ekosi Health partners with Cerebra to evaluate clinical cannabinoid therapy on sleep quality
Manitoba-based healthcare provider and medical technology company collaborate to provide valuable insights into practical healthcare
November 8, 2022 By Grow Opportunity Staff
(Globe Newswire) Gimli, Man. — Ekosi Health, a Canadian-based and Indigenous-owned healthcare provider specializing in clinical cannabinoid therapy, has partnered with Cerebra, a leading sleep technology company. The partners are running an observational study that will assess the effectiveness of cannabinoid therapy on sleep quality.
Believed to be the first study of its kind in the field, Cerebra’s sleep system and its proprietary odd ratio product (ORP) sleep depth metric are being utilized in the comfort of participants’ homes to evaluate the effectiveness of cannabinoid therapy, objectively.
With over 27,000 patient interactions, Ekosi Health has seen success in improving conditions ranging from chronic pain to substance misuse. Although some preliminary evidence shows a positive impact on sleep improvement from cannabinoid therapy, mixed results remain highlighting the need for a landmark study and further research.
“The Cerebra sleep system uses a patented algorithm ORP that micro-analyses the electroencephalogram (EEG) signal providing a continuous measure of sleep depth, moving beyond conventional scoring methods to dig deeper into brain activity.” — Dr. Amy Bender, Cerebra’s director of clinical sleep science
The origin of the observational study arose as a result of the Bioscience Association of Manitoba’s Advancing Healthcare Initiative (AHI), funded by Prairies Economic Development Canada. This initiative was designed to connect healthcare innovators with clinicians to assess and assist in the real-world application and evaluation of innovators’ technologies, inspiring collaborations like Ekosi Health and Cerebra’s.
“Ekosi Health’s mission is to improve the quality of life for individuals seeking knowledge of, and safe access to, cannabis and other plant-based medicines. This study assists in achieving that mission and provides participants looking for relief with an innovative and personalized experience.” — Dr. Shelley Turner, chief medical officer of Ekosi Health
Print this page
